<DOC>
	<DOCNO>NCT01237262</DOCNO>
	<brief_summary>The efficacy TNF alfa inhibitor treatment psoriasis document many study . Their effect dendritic cell scarcely study . TNF- α central role dendritic cell biology , maturity mobilization peripheral tissue secondary lymphoid organ . The primary objective study : - To document absolute number , density immune infiltrate dendritic cell inflammatory cytokine expression pattern ( particularly IFN α IL-32 ) psoriasic lesion vs normal skin patient - To describe change cell number expression pattern upon 16 week treatment TNF alfa inhibitor .</brief_summary>
	<brief_title>Evaluation Lymphocytic Infiltrate , Dendritic Cells Cytokines Expression Psoriatic Lesion Normal Skin Before After TNF Alfa Inhibitors Therapy</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Male female subject &gt; 18 year age , affect moderate severe psoriasis Subject clinical diagnosis psoriasis least 12 month , stable plaque psoriasis least 2 month screen ( subject concurrent psoriatic arthritis may enrol ) . Subject naıve TNFantagonist therapy efalizumab . Subjects consider eligible accord follow tuberculosis screen criterion : 1 . Have history latent active TB prior screen ; 2 . Have sign symptom suggestive active TB upon medical history and/or physical examination ; 3 . Within 1 month prior first administration study medication , negative diagnostic tuberculin skin test . Normal chest Xray within 3 month prior screen evidence malignancy , infection , current old TB . Subjects ' screen baseline clinical data must within normal limit , include result medical history , physical examination laboratory evaluation ( complete blood count , serum value liver enzyme , bilirubin , glucose , albumin , creatinine urine analysis ) . Willing able comply protocol requirement duration study . Women childbearing potential must use adequate birth control measure throughout study 150 day ( 5 month ) study completion . Pregnant breastfeed woman , woman plan pregnancy . Patients suitable TNF alfa inhibitor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>immune infiltrate</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>cytokine expression</keyword>
</DOC>